Medication Use Patterns and Predictors of Nonpersistence and Nonadherence with Oral 5-Aminosalicylic Acid Therapy

Abstract

BACKGROUND: 5-aminosalicylic acid (5-ASA) is the recommended firstline treatment for active mild-to-moderate ulcerative colitis (UC) and for maintenance of UC remission. However, persistence and adherence to prescribed 5-ASAs are often suboptimal.

Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse

“…serum drug levels, clinical drug effects) 11. Patients with an average MPR ≥80% were classed as adherent; this is in line with previous adherence studies conducted in IBD 6–12. Patients with an average MPR >200% over the whole study period were excluded from the analysis.…”

“…11 Patients with an average MPR ≥80% were classed as adherent; this is in line with previous adherence studies conducted in IBD. 6,12 Patients with an average MPR >200% over the whole study period were excluded from the analysis. Ostensibly, excessive adherence rates typically arise through anomalies in dispensing or refill practice, for example, if a patient receives half of their prescribed medication in one dispensing followed by the remainder the following day, they would record an MPR of several thousand per cent.…”

Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis

“…Yen et al 22 reported in 2012 found that being younger than 65 years and being female were independently associated with nonadherence in the real world. Our study population generated different conclusions; older patients and females were less adherent to rectal administration.…”

Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis

“…16,17 Our understanding of adherence behavior in patients with IBD is thus incomplete, as the methodology of many studies only allows examination of surrogate markers of beliefs or behaviors, such as gender or socioeconomic status, rather than patient-reported barriers to adherence. 2,18,19 Data from other diseases have identified patient-reported barriers to adherence, but these results may not be applicable to the IBD population because of the different demographic distributions of these conditions; the concerns of a woman aged 50 years with breast cancer may not mirror those of a college student aged 20 years with colitis. 20 Qualitative-based research has illustrated that enhancing medication-taking behavior in patients with IBD requires a more in-depth examination of patients' motivations.…”